A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects

NCT01171313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: XP21279 and carbidopa (experimental)
DRUG: Sinemet (comparator)
DRUG: Placebo for XP21279 and carbidopa
DRUG: Placebo for Sinemet

Sponsor

XenoPort, Inc.